- Home
- CMPS vs INBX Comparison
CMPS vs INBX Comparison
Compare CMPS & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPS
- INBX
- Stock Information
- Founded
- CMPS 2020
- INBX 2010
- Country
- CMPS United Kingdom
- INBX United States
- Employees
- CMPS N/A
- INBX N/A
- Industry
- CMPS Biotechnology: Pharmaceutical Preparations
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- CMPS Health Care
- INBX Health Care
- Exchange
- CMPS Nasdaq
- INBX Nasdaq
- Market Cap
- CMPS 487.4M
- INBX 430.2M
- IPO Year
- CMPS 2020
- INBX 2020
- Fundamental
- Price
- CMPS $6.34
- INBX $33.88
- Analyst Decision
- CMPS Strong Buy
- INBX Hold
- Analyst Count
- CMPS 7
- INBX 2
- Target Price
- CMPS $17.00
- INBX N/A
- AVG Volume (30 Days)
- CMPS 1.5M
- INBX 123.8K
- Earning Date
- CMPS 10-30-2025
- INBX 11-13-2025
- Dividend Yield
- CMPS N/A
- INBX N/A
- EPS Growth
- CMPS N/A
- INBX N/A
- EPS
- CMPS N/A
- INBX N/A
- Revenue
- CMPS N/A
- INBX $1,400,000.00
- Revenue This Year
- CMPS N/A
- INBX $563.00
- Revenue Next Year
- CMPS N/A
- INBX $230.77
- P/E Ratio
- CMPS N/A
- INBX N/A
- Revenue Growth
- CMPS N/A
- INBX N/A
- 52 Week Low
- CMPS $2.25
- INBX $10.81
- 52 Week High
- CMPS $6.63
- INBX $37.53
- Technical
- Relative Strength Index (RSI)
- CMPS 73.27
- INBX 70.20
- Support Level
- CMPS $5.54
- INBX $31.75
- Resistance Level
- CMPS $6.62
- INBX $37.53
- Average True Range (ATR)
- CMPS 0.33
- INBX 1.99
- MACD
- CMPS 0.08
- INBX 0.27
- Stochastic Oscillator
- CMPS 86.39
- INBX 67.38
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.